Freedom Center Of Worcester is a medicare approved dialysis facility center in Worcester, Massachusetts and it has 5 dialysis stations. It is located in Worcester county at 1 Innovation Drive, Worcester, MA, 01605. You can reach out to the office of Freedom Center Of Worcester at (508) 767-3950. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Freedom Center Of Worcester has the following ownership type - Profit. It was first certified by medicare in July, 2016. The medicare id for this facility is 222590 and it accepts patients under medicare ESRD program.
| Name | Freedom Center Of Worcester |
|---|---|
| Location | 1 Innovation Drive, Worcester, Massachusetts |
| No. of Dialysis Stations | 5 |
| Medicare ID | 222590 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1 Innovation Drive, Worcester, Massachusetts, 01605 | |
| (508) 767-3950 | |
| Not Available |
News Archive
Students around the world now have free access to the same leading engineering simulation solutions used by top organizations and professional engineers to create the most advanced products on the planet, thanks to ANSYS.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Qatar University Research Office have announced the winners of the Qatar University Scientists 2015 Scopus Awards.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
Publication in Nature advanced on line publication : researchers at the Université libre de Bruxelles, ULB identify distinct types of stem cells that contribute to mammary gland development and maintenance.
› Verified 8 days ago
| NPI Number | 1497125678 |
| Organization Name | Freedom Center Of Worcester |
| Doing Business As | Bio-medical Applications Of Massachusetts, Inc. |
| Address | 1 Innovation Dr Worcester, Massachusetts, 01605 |
| Phone Number | (508) 767-3950 |
News Archive
Students around the world now have free access to the same leading engineering simulation solutions used by top organizations and professional engineers to create the most advanced products on the planet, thanks to ANSYS.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Qatar University Research Office have announced the winners of the Qatar University Scientists 2015 Scopus Awards.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
Publication in Nature advanced on line publication : researchers at the Université libre de Bruxelles, ULB identify distinct types of stem cells that contribute to mammary gland development and maintenance.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 14 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 43 |
News Archive
Students around the world now have free access to the same leading engineering simulation solutions used by top organizations and professional engineers to create the most advanced products on the planet, thanks to ANSYS.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Qatar University Research Office have announced the winners of the Qatar University Scientists 2015 Scopus Awards.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
Publication in Nature advanced on line publication : researchers at the Université libre de Bruxelles, ULB identify distinct types of stem cells that contribute to mammary gland development and maintenance.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular peritoneal dialysis at the center | 33 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 220 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 96 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Students around the world now have free access to the same leading engineering simulation solutions used by top organizations and professional engineers to create the most advanced products on the planet, thanks to ANSYS.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Qatar University Research Office have announced the winners of the Qatar University Scientists 2015 Scopus Awards.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
Publication in Nature advanced on line publication : researchers at the Université libre de Bruxelles, ULB identify distinct types of stem cells that contribute to mammary gland development and maintenance.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Freedom Center Of Worcester with elevated calcium levels.
| Patients with hypercalcemia | 38 |
| Hypercalcemia patient months | 243 |
| Patients with Serumphosphor | 40 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 30 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 20 |
News Archive
Students around the world now have free access to the same leading engineering simulation solutions used by top organizations and professional engineers to create the most advanced products on the planet, thanks to ANSYS.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Qatar University Research Office have announced the winners of the Qatar University Scientists 2015 Scopus Awards.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
Publication in Nature advanced on line publication : researchers at the Université libre de Bruxelles, ULB identify distinct types of stem cells that contribute to mammary gland development and maintenance.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 4 |
| Patient months included in arterial venous fistula and catheter summaries | 17 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
Students around the world now have free access to the same leading engineering simulation solutions used by top organizations and professional engineers to create the most advanced products on the planet, thanks to ANSYS.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Qatar University Research Office have announced the winners of the Qatar University Scientists 2015 Scopus Awards.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
Publication in Nature advanced on line publication : researchers at the Université libre de Bruxelles, ULB identify distinct types of stem cells that contribute to mammary gland development and maintenance.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 5 |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
Students around the world now have free access to the same leading engineering simulation solutions used by top organizations and professional engineers to create the most advanced products on the planet, thanks to ANSYS.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Qatar University Research Office have announced the winners of the Qatar University Scientists 2015 Scopus Awards.
Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
Publication in Nature advanced on line publication : researchers at the Université libre de Bruxelles, ULB identify distinct types of stem cells that contribute to mammary gland development and maintenance.
› Verified 8 days ago